How many insider trades does FilingIQ track for LIXT?

FilingIQ tracks 50 Form 4 insider transactions for LIXT (LIXTE BIOTECHNOLOGY HOLDINGS, INC.), covering filings from Jan 21, 2016 onwards. 12 of those were filed in the last 90 days.

Are LIXT insiders net buyers or net sellers?

Across the full Form 4 history for LIXT, 30 transactions (60%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does LIXT insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is LIXT in?

LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $26.89M.

LIXT insider trading

NasdaqCM Healthcare

LIXTE BIOTECHNOLOGY HOLDINGS, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

60% / 0%

Market cap

$26.89M

About LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Company website: lixte.com

LIXT insider activity at a glance

FilingIQ has scored 50 insider transactions for LIXT since Jan 21, 2016. The most recent filing in our index is dated Apr 15, 2026.

Across the full history, 30 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on LIXT insider trades is 62.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live LIXT trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for LIXT?: FilingIQ tracks 50 Form 4 insider transactions for LIXT (LIXTE BIOTECHNOLOGY HOLDINGS, INC.), covering filings from Jan 21, 2016 onwards. 12 of those were filed in the last 90 days.
Are LIXT insiders net buyers or net sellers?: Across the full Form 4 history for LIXT, 30 transactions (60%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does LIXT insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is LIXT in?: LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $26.89M.

Methodology & sources

Every LIXT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.